CGTX
ANALYST COVERAGE7 analysts
BUY
Buy
686%
Hold
114%
6 Buy (86%)1 Hold (14%)0 Sell (0%)
Full report →
Key MetricsTTM
Market Cap$92.71M
Revenue TTM
Net Income TTM
Free Cash Flow
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
Return on Equity-72.7%
Return on Assets-54.2%
Debt / Equity
Current Ratio5.92
EPS TTM
PRICE
Prev Close
1.25
Open
1.25
Day Range1.22 – 1.26
1.22
1.26
52W Range0.22 – 3.83
0.22
3.83
29% of range
VOLUME & SIZE
Avg Volume
1.1M
FUNDAMENTALS
P/E Ratio
-5.5x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
0.85
Market-like
TECHNICAL
RSI (14)
58
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 24
DEx-Dividend
In 90 days
Aug 21
PDividend Pay
In 128 days
Sep 28

CGTX News

About

cognition therapeutics inc. is a drug discovery and development company located in pittsburgh, pennsylvania. founded in 2007, the company uses proprietary biology and chemistry platforms to discover novel drug targets and disease modifying therapies for disorders of the central nervous system.

Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Anita CornetHead of Quality
Anthony O. CaggianoChief Medical Officer
Steven A. WeissmanVice President & Head of CMC
Bobby HornCorporate Controller
John Brendan DoyleChief Financial Officer
Lisa RicciardiChief Executive Officer, President & Director